DEXCOM CLASS ACTION LAWSUIT: DexCom, Inc. (NASDAQ:DXCM) Investors with Losses are Notified of the Upcoming December 26 Court Deadline

Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. and its senior executives for securities fraud following significant stock declines attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until December 26, 2025, to request to lead the case, which is pending in the U.S. District Court for the Southern District of New York [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of DexCom investors [2]. Group 2: Product Issues - DexCom manufactures continuous glucose monitoring systems, including the G6 and G7, which were marketed as highly accurate [3]. - Allegations state that unauthorized design changes were made to the G6 and G7, compromising their accuracy and exposing users to health risks [4]. Group 3: Stock Performance - DexCom's stock experienced significant declines due to quality issues with the G6 and G7, including a drop of $7.12 per share (over 9%) following an FDA warning letter on March 7, 2025 [5]. - After the FDA published the warning letter on March 25, 2025, the stock fell an additional $3.19 per share (over 4%) [6]. - A report by Hunterbrook on September 18, 2025, revealed serious safety concerns, leading to a nearly 12% drop in stock price, equating to $8.99 per share [7].